Gene therapy using haematopoietic stem and progenitor cells.

Area of Science:

• Biomedical Science
• Gene Therapy
• Hematology

Background:

• Gene therapy using hematopoietic stem and progenitor cells (HSPCs) is an established treatment for monogenic blood disorders.
• Approved therapies utilize lentiviral and gammaretroviral vectors for HSPC correction.
• Gene editing technologies like CRISPR-Cas9 offer promising clinical applications for HSPC modification.

Purpose of the Study:

• To review recent advancements in HSPC gene therapy.
• To discuss novel strategies for applying HSPC gene therapy to various diseases.
• To highlight the potential of engineered HSPCs beyond hematological conditions.

Main Methods:

• Review of current literature on HSPC gene therapy.
• Analysis of approved and emerging gene therapy vectors (lentiviral, gammaretroviral).
• Examination of gene editing techniques (CRISPR-Cas9) for HSPC modification.
• Exploration of preclinical data on cross-correction of non-hematopoietic cells.

Main Results:

• HSPC gene therapy is effective for primary immunodeficiencies and β-thalassaemia.
• Approved gene therapies demonstrate the clinical viability of corrected autologous HSPCs.
• Gene editing shows significant promise for precise genomic modification of HSPCs.
• Preclinical evidence supports the use of engineered HSPCs for neurodegenerative metabolic diseases.

Conclusions:

• HSPC gene therapy continues to evolve as a powerful therapeutic approach.
• The application of HSPC gene therapy is expanding beyond blood disorders.
• Engineered HSPCs hold potential for treating a wider spectrum of genetic and degenerative diseases.